1. Fine RN, Becker Y, De Geest S, Eisen H, Ettenger R, Evans R, Rudow DL, McKay D, Neu A, Nevins T, Reyes J, Wray J, Dobbels F. Non-adherence consensus conference summary report. Am J Transplant. 2009;9:35–41.
2. World Health Organization. (2001). Innovative care for chronic conditions. Building blocks for actions. World Health Organization, www.who.int/chp/knowledge/publications/icccglobalreport.pdf?ua=1 (Assessed at July 2, 2014).
3. Wu EQ, Guerin A, Yu AP, Bollue VK, Guo A, Griffin JD. Retrospective real-world comparison of medical visits, costs and adherence between nilitinib and dasatinib in chronic myeloid leukaemia. Curr Med Res Opin. 2010;26(12):2861–9.
4. Leendertse AJ, Egberts ACG, Stoker LJ, van den Bemt PMLA. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med. 2008;168(17):1890–6.
5. Sabaté, E. (2003). Adherence to long-term therapies, evidence for action. World Health Organization, apps.who.int /medicinedocs/pdf/s4883e/s4883e.pdf (Assessed at July 2, 2014).